Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization

Rhea-AI Summary

Integra LifeSciences (Nasdaq: IART) will present new real-world data on PriMatrix dermal scaffold at three April 2026 conferences.

Highlights include analyses from 985 cases involving 117 surgeons, plus a 23-patient burn case series, covering diabetic foot ulcers, complex wounds and mixed-thickness burns.

Positive

• Analysis of 985 cases covering diverse wound types
• Data collected from 117 surgeons, indicating broad clinical input
• A 23-patient case series on burn wound bed readiness
• Planned presentations at three major conferences (Apr 8–17, 2026)

Negative

• None.

News Market Reaction – IART

+0.21%

1 alert

+0.21% News Effect

On the day this news was published, IART gained 0.21%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PriMatrix cases: 985 cases Participating surgeons: 117 surgeons Burn case series size: 23 patients +3 more

6 metrics

PriMatrix cases 985 cases Real-world PriMatrix Dermal Scaffold analyses across multiple wound types

Participating surgeons 117 surgeons Surgeons involved in PriMatrix real-world utilization data set

Burn case series size 23 patients Case series on PriMatrix for burn injuries with comorbidities

DLS conference dates April 8–11 Functional Diabetic Limb Salvage Conference, Washington, D.C.

SAWC/WHS dates April 8–12 SAWC Spring | WHS Conference, Charlotte, North Carolina

ABA meeting dates April 14–17 American Burn Association Annual Meeting, Orlando, Florida

Market Reality Check

Price: $9.90 Vol: Volume 637,110 vs 20-day ...

normal vol

$9.90 Last Close

Volume Volume 637,110 vs 20-day average 851,489, showing lighter trading ahead of the PriMatrix data presentations. normal

Technical Shares at $9.31 are trading below the 200-day moving average of $12.61 and sit well under the $21.34 52-week high, though above the $8.70 52-week low.

Peers on Argus

IART’s -2.31% prior-day move contrasts with sector peers where only BBNX appears...

1 Up

IART’s -2.31% prior-day move contrasts with sector peers where only BBNX appears in momentum scanners, up 5.429999902844429% without news. Other peers show mixed, smaller moves, suggesting today’s story is company-specific rather than a broad medical device rotation.

Common Catalyst Selective product-portfolio news in medical devices, with peers like ESTA also highlighting device adoption milestones.

Historical Context

5 past events · Latest: Feb 26 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings & guidance	Negative	-2.2%	Q4 and 2025 results with GAAP loss and detailed 2026 financial guidance.
Feb 17	Leadership changes	Positive	+1.1%	Multiple executive appointments, including a new CTO and chief legal officer.
Feb 09	Earnings call notice	Neutral	-2.9%	Announcement of timing and access details for Q4 and full-year 2025 call.
Jan 05	Conference presentation	Neutral	+4.5%	Planned CEO and CFO presentation at the J.P. Morgan Healthcare Conference.
Dec 01	Conference appearance	Neutral	+0.8%	CEO and CFO presentation at Citi’s 2025 Global Healthcare Conference.

Pattern Detected

Recent IART news has generally produced modest single-day moves, with both positive and negative reactions, and no consistent pattern of overreaction to non-earnings announcements.

Recent Company History

Over the last several months, Integra’s news flow has centered on earnings, leadership changes, and investor conference appearances. The Q4 and full-year 2025 results and 2026 guidance release on Feb 26, 2026 drew a mild negative reaction, while executive leadership appointments on Feb 17, 2026 were received positively. Conference-related communications on Jan 5, 2026 and Dec 1, 2025 produced modest gains. Today’s PriMatrix real-world evidence update fits within this pattern of operational and clinical detail without a clear historical tendency toward large price swings.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-26

Integra has an effective Form S-3ASR shelf registration dated Feb 26, 2026, covering common stock, preferred stock, debt securities, warrants, purchase contracts and units for potential future offerings. The filing notes Nasdaq listing under IART and reflects 77,886,634 common shares issued with 14,398,724 held as treasury stock as of Dec 31, 2025. No usage has been recorded yet in the provided data.

Market Pulse Summary

This announcement highlights expanded real-world experience with PriMatrix, including 985 cases from...

Analysis

This announcement highlights expanded real-world experience with PriMatrix, including 985 cases from 117 surgeons and a 23-patient burn injury series, to be showcased at multiple April conferences. In the context of recent earnings and transformation efforts, it underscores Integra’s emphasis on evidence-based wound reconstruction. Investors may watch for how these data influence clinician adoption across wound types and track future regulatory filings or capital decisions under the existing S-3ASR shelf framework.

Key Terms

real-world data, dermal scaffold, fetal bovine dermal matrix, diabetic foot ulcers, +4 more

8 terms

real-world data medical

"will present new real-world data on PriMatrix® Dermal Scaffold at three major"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

dermal scaffold medical

"real-world data on PriMatrix® Dermal Scaffold at three major medical conferences"

A dermal scaffold is a medical product that acts like temporary scaffolding for the skin, providing a physical framework that supports new tissue growth and guides wound healing. Investors should care because its effectiveness, safety and ease of use drive clinical adoption, regulatory approval chances, pricing and reimbursement, and the size of the market opportunity; better scaffolds can shorten recovery, reduce complications and influence competitive positioning in wound care.

fetal bovine dermal matrix medical

"PriMatrix, a fetal bovine dermal matrix, across a broad range of wound types"

A fetal bovine dermal matrix is a medical product made by processing cow fetal skin into a collagen-rich, sponge-like scaffold that supports wound healing and tissue repair. Think of it as a biologic bandage or framework that helps a patient’s own cells grow back in damaged tissue. Investors track these products because their sales, regulatory approvals, safety profile, supply chain and reimbursement status directly affect medical-device company revenue and valuation.

diabetic foot ulcers medical

"Performance of Fetal Bovine Dermis in Diabetic Foot Ulcers (DFU): Insights from"

A diabetic foot ulcer is an open sore or wound on the foot that occurs when high blood sugar and nerve damage prevent normal healing, much like a small pothole that keeps widening because the road can’t be properly repaired. It matters to investors because these wounds drive demand for treatments, medical devices, wound-care drugs and hospital services, and they carry risks of infection and amputation that can shape healthcare costs, reimbursement decisions and clinical trial opportunities.

case series medical

"a 23-patient case series outlines clinical experience with PriMatrix in support"

A case series is a report that describes a group of patients who received the same treatment or have the same condition, summarizing their outcomes without a comparison group. For investors, it’s an early, real-world snapshot—like a photo album of selected cases—that can suggest potential benefit or safety signals but cannot prove effectiveness or predict broader results, so it should be weighed cautiously alongside larger, controlled studies.

wound bed readiness medical

"case series outlines clinical experience with PriMatrix in support of wound bed readiness"

Wound bed readiness describes whether the surface and environment of an open wound have been prepared so healing or a closure treatment can work effectively; it usually means dead tissue and infection are controlled, moisture is balanced, and blood flow is adequate. For investors, it signals how well a product or therapy can perform in real-world use and influences clinical outcomes, adoption by clinicians, and regulatory or reimbursement success — like making sure a garden bed is properly tilled before planting.

mixed thickness burn injuries medical

"Fetal Bovine Dermal Scaffold in the Management of Mixed Thickness Burn Injuries"

Mixed thickness burn injuries are wounds that affect more than one layer of the skin, with some areas being shallower and others deeper; imagine a surface with both light scrapes and deeper cuts in different spots. For investors, these injuries matter because they typically require more complex and prolonged medical care, can drive higher treatment and insurance costs, increase the risk of long-term disability or litigation, and may disrupt workforce or operations.

full and partial thickness burn injuries medical

"Fetal Bovine Dermal Scaffold in the Management of Full and Partial Thickness Burn Injuries."

Full and partial thickness burn injuries describe how deeply a burn damages the skin: partial-thickness harms the outer layer and part of the layer beneath it, while full-thickness destroys both layers and often underlying tissue. Depth matters to investors because deeper burns usually require more complex medical care, longer recovery, specialized products or surgeries, and higher treatment costs, all of which affect demand, clinical trial outcomes, reimbursement and company revenues—think of it like replacing a single coat of paint versus rebuilding a wall.

AI-generated analysis. Not financial advice.

Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April

PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will present new real-world data on PriMatrix^® Dermal Scaffold at three major medical conferences in April. The data include new analyses from 985 cases involving 117 surgeons, highlighting the use of PriMatrix, a fetal bovine dermal matrix, across a broad range of wound types, including surgical, traumatic and chronic ulcers, as well as complex wounds with tunneling and undermining features.^1,2,3 In addition, a 23-patient case series outlines clinical experience with PriMatrix in support of wound bed readiness in burn injuries, including patients with significant comorbidities.⁴ Findings will be shared at the Functional Diabetic Limb Salvage Conference (April 8–11 in Washington, D.C.), the Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) Conference (April 8–12 in Charlotte, North Carolina) and the American Burn Association Annual Meeting (April 14–17 in Orlando, Florida).

Key PriMatrix Data Presentations Include:

• Performance of Fetal Bovine Dermis in Diabetic Foot Ulcers (DFU): Insights from Real-world Clinical Use (Poster at the DLS Conference in Washington D.C.)
• Real-World Utilization of Fetal Bovine Dermis: A Clinician-Reported Snapshot (Poster at the SAWC Spring Conference in Charlotte, North Carolina)
• Real-World Outcomes Using Fetal Bovine Dermis for Complex Wounds (Poster at the SAWC Spring Conference in Charlotte, North Carolina)
• Fetal Bovine Dermal Scaffold in the Management of Mixed Thickness Burn Injuries (Poster at the ABA Conference in Orlando, Florida)

“PriMatrix is incorporated into our clinical practice across a range of challenging wound scenarios,” said John S. Steinberg, DPM, FACFAS, codirector of the Center for Wound Healing at MedStar Georgetown University Hospital. “The availability of clinical data helps inform decision making in complex reconstruction cases. Our team often includes PriMatrix as part of our established surgical workflow for many of our critical limb salvage patients.”

Additional presentations at the April conferences will showcase advancements and real-world outcomes across Integra’s broader wound reconstruction and care portfolio – including Integra^® Dermal Matrices, Cytal^® Wound Matrix, MicroMatrix^® and AmnioExcel^® – reinforcing the company’s evidence-based solutions.

“These results add to a growing body of evidence showing how PriMatrix meaningfully influences outcomes in wound reconstruction,” said Raymond Turner, MD, corporate vice president and chief medical officer at Integra LifeSciences. “We’ve seen strong recent engagement with PriMatrix from surgeons, reflected in an increasing volume of clinical use and interest across care settings. By offering a broad and clinically validated portfolio, we support highly tailored approaches that help advance transformational care across acute and chronic wounds, burns, trauma and reconstructive procedures.”

References

1. Dai Y, Evans J, Leonard M, Arnold Y, Searcy P. Performance of Fetal Bovine Dermis in Diabetic Foot Ulcers: Insights from Real-World Clinical Use. Poster presented at the Diabetic Limb Salvage Conference; April 2026; Washington, D.C.
2. Dai Y, Asuku M, Leonard M, Siebeneck A, Arnold Y, Searcy P. Real-World Utilization of Fetal Bovine Dermis: A Clinician-Reported Snapshot. Poster presented at the Society of Advanced Wound Care Spring Meeting; April 2026; Charlotte, North Carolina.
3. Dai Y, Leonard M, Asuku M, Siebeneck A, Arnold Y, Searcy P. Real-World Outcomes Using Fetal Bovine Dermis for Complex Wounds. Poster presented at the Society of Advanced Wound Care Spring Meeting; April 2026; Charlotte, North Carolina.
4. Young V, Svirsky N, Pruim A, Shihadeh S, Miller K, Cordova AC. Fetal Bovine Dermal Scaffold in the Management of Full and Partial Thickness Burn Injuries. Poster presented at the American Burn Association Annual Meeting; April 2026; Orlando, Florida.

About Integra

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. These forward-looking statements include, but are not limited to, statements related to the potential applications and efficacy of the Integra products described herein and the realization of improvements to health outcomes. There can be no assurance that these products will achieve the benefits described herein or that such benefits will be replicated. The actual effect of the use of these products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra's Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00cf1e29-7492-4f89-bab1-6691cf2253c4

FAQ

What PriMatrix findings will Integra (IART) present at the April 2026 conferences?

Key findings include real-world analyses of PriMatrix from 985 cases and a 23-patient burn series. According to the company, presentations span diabetic foot ulcers, complex wounds and mixed-thickness burns at three April 2026 meetings.

How large was the clinical dataset on PriMatrix reported by Integra (IART)?

The dataset includes 985 clinical cases and involvement of 117 surgeons. According to the company, that dataset provides a clinician-reported snapshot across surgical, traumatic, chronic and complex wound types.

Which April 2026 meetings will feature Integra (IART) PriMatrix posters and presentations?

Presentations will appear at DLS, SAWC Spring|WHS and the ABA annual meeting in April 2026. According to the company, dates span April 8–17, 2026 across Washington D.C., Charlotte and Orlando.

Does the Integra (IART) data include burn-specific clinical experience with PriMatrix?

Yes — a 23-patient case series addresses PriMatrix use for burn wound bed readiness. According to the company, the series includes patients with significant comorbidities and mixed-thickness injuries.

What wound types are covered by Integra's (IART) PriMatrix real-world analyses?

Analyses cover diabetic foot ulcers, surgical and traumatic wounds, chronic ulcers, and complex wounds with tunneling/undermining. According to the company, results reflect broad clinical use across acute and chronic wound settings.